"These disappointing results underscore the difficulty of treating pancreatic cancer, which remains a major unmet medical need."
– Sean E. Harper, executive vice president of Research and Development at Amgen Inc. commenting on the company's decision to stop the ganitumab Phase III GAMMA (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial

"For those of you who like sports, it's kind of a jinx to start celebrating when you win your first playoff game because the goal is to win the championship. We have to deliver this product [Qsymia] to patients. We will not be satisfied until we get the product out."
– Leland Wilson, Vivus CEO speaking at the company's analyst day

"Our partnership with Nodality exemplifies Pfizer's commitment to precision medicine by providing us with earlier insight into a compound's potential clinical profile."
– Jose-Carlos Gutierrez-Ramos, senior vice president, BioTherapeutics R&D at Pfizer Inc.